Laura Kartner
PhD Candidate, Clinical Psychologist & Researcher at the Central Institute of Mental Health
Data updated
Research Footprint
Laura Kartner appears in 8 tracked papers (2021–2026), most studied alongside Psilocybin, Placebo and LSD, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression (222 citations).
Frequent co-authors: Lea Mertens, Robin Carhart-Harris and David Nutt.
Background & Research
Laura Kärtner is a clinical psychologist and researcher whose work focuses on the therapeutic potential and psychobiological mechanisms of psychoactive substances, especially psilocybin and related context effects. She studied psychology at Julius-Maximilians-University Würzburg and joined the Department of Molecular Neuroimaging at the Central Institute of Mental Health in Mannheim for her PhD and clinical training. Her publications include studies on psilocybin-assisted therapy, microdosing, therapeutic alliance, and psychedelic psychotherapy.
Key Impact
She is a recurring author on influential psychedelic research spanning psilocybin therapy, microdosing, connectedness, and psychotherapy mechanisms.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Laura Kartner is associated with.
Central Institute of Mental Health, Mannheim
The Central Institute of Mental Health (ZI Mannheim) is a leading German psychiatric research institute affiliated with Heidelberg University, and under Prof. Dr. Gerhard Gründer is one of Europe’s foremost centers for psychedelic research—co-leading EPIsoDE, Germany’s first federal government-funded (BMBF, €2.2M) Phase II RCT of psilocybin for treatment-resistant depression, and receiving one of the first compassionate-use approvals for psilocybin in Germany and the EU, with results published in Lancet Psychiatry in 2025. The institute also conducts molecular neuroimaging research on MDMA and psilocybin mechanisms, and has reported successful ketamine treatment outcomes in treatment-resistant depression.
View stakeholder →Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg
The Central Institute of Mental Health (Zentralinstitut für Seelische Gesundheit, ZI) is a psychiatric research and treatment center in Mannheim affiliated with the Medical Faculty Mannheim of Heidelberg University, providing research, teaching and clinical services in psychiatry, psychotherapy, child and adolescent psychiatry, psychosomatic medicine and addiction medicine.
View stakeholder →Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →